摘要
【目的】探讨辛伐他汀联合常规治疗对早期糖尿病肾病(DN)患者肾功能及肾组织纤维化的影响。【方法】本院收治的88例早期DN患者,随机分成观察组(辛伐他汀联合常规血糖控制治疗)与对照组(常规血糖控制治疗),每组44例。比较两组治疗后临床有效率,肾功能指标[血肌酐(SCr)、尿素氮(BUN)、β2微球蛋白(β2-MG)、尿白蛋白肌酐比(UACR)、24h尿蛋白定量],肾纤维化指标[Ⅳ型胶原(Ⅳ-C)、转化生长因子(TGF-β1)、组织基质金属蛋白酶抑制剂-1(TIMP-1)]水平以及用药后不良反应发生情况。【结果】治疗后,观察组总有效率为86.36%(38/44),高于对照组的65.91%(29/44),且差异有统计学意义(P<0.05);两组SCr、BUN、β2-MG、UACR、24h尿蛋白量水平较治疗前均降低(P<0.05),且观察组低于对照组(P<0.05);两组Ⅳ-C、TGF-β1、TIMP-1水平较治疗前均降低(P<0.05),且观察组低于对照组(P<0.05)。观察组不良反应总发生率为18.18%(8/44),与对照组的25.00%(11/44)相比较差异无统计学意义(P>0.05)。【结论】辛伐他汀联合常规治疗可提高早期DN患者的治疗有效率,改善肾功能,减缓肾组织纤维化进程,且安全性较高。
【Objective】To explore the effect of simvastatin combined with conventional treatment on renal function and renal tissue fibrosis in patients with early diabetic nephropathy.【Methods】A total of 88 patients with early diabetic nephropathy who were admitted to our hospital were selected and randomly divided into the observation group(simvastatin combined with conventional treatment)and the control group(conventional blood glucose control),with 44 cases in each group.The control group received conventional blood glucose control,while the observation group received simvastatin in addition to the conventional blood glucose control group.The clinical effective rate,renal function indexes[serum creatinine(SCr),urea nitrogen(BUN),β2-microglobulin(β2-MG),urinary albumin-to-creatinine ratio(UACR),and 24-hour urinary protein quantitation],renal fibrosis indexes[type IV collagen(Ⅳ-C),transforming growth factor(TGF-β1),and tissue matrix metalloproteinase inhibitor-1(TIMP-1)]were compared between the two groups after treatment,and the adverse drug reactions during treatment were observed as well.【Results】After treatment,the total effective rate in the observation group was 86.36%(38/44),which was higher than 65.91%(29/44)in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of SCr,BUN,β2-MG,UACR and 24h urinary protein in both groups decreased(P<0.05),and the observation group showed even lower level(P<0.05).After treatment,the levels ofⅣ-C,TGF-β1 and TIMP-1 in the two groups decreased(P<0.05),and the comparison between the two groups showed that the level in the observation group were lower than the control group(P<0.05).The adverse reactions of the observation group was 18.18%(8/44)and of the control group was 25.00%(11/44),which showed no difference(P>0.05).【Conclusion】Simvastatin combined with conventional treatment can improve the clinical efficiency and renal function,while slow down the process of renal fibrosis in patients with early diabetic nephropathy,with high safety.
作者
殷俊
邱君思
邵芳
YIN Jun;QIU Jun-si;SHAO Fang(Department of Nephrology,Wuxi Second People's Hospital,Wuxi Jiangsu 214000,China)
出处
《医学临床研究》
CAS
2022年第4期550-552,556,共4页
Journal of Clinical Research
